KR102690998B1 - 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도 - Google Patents

항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도 Download PDF

Info

Publication number
KR102690998B1
KR102690998B1 KR1020187004745A KR20187004745A KR102690998B1 KR 102690998 B1 KR102690998 B1 KR 102690998B1 KR 1020187004745 A KR1020187004745 A KR 1020187004745A KR 20187004745 A KR20187004745 A KR 20187004745A KR 102690998 B1 KR102690998 B1 KR 102690998B1
Authority
KR
South Korea
Prior art keywords
antibody
seq
ser
tfr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187004745A
Other languages
English (en)
Korean (ko)
Other versions
KR20180028519A (ko
Inventor
피에르 로네이
코랄리 베란즈
에르브 쏘쉐
Original Assignee
이나터리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이나터리 filed Critical 이나터리
Publication of KR20180028519A publication Critical patent/KR20180028519A/ko
Application granted granted Critical
Publication of KR102690998B1 publication Critical patent/KR102690998B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020187004745A 2015-07-22 2016-07-21 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도 Active KR102690998B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306192 2015-07-22
EP15306192.4 2015-07-22
PCT/EP2016/067465 WO2017013230A1 (en) 2015-07-22 2016-07-21 ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS

Publications (2)

Publication Number Publication Date
KR20180028519A KR20180028519A (ko) 2018-03-16
KR102690998B1 true KR102690998B1 (ko) 2024-07-31

Family

ID=53776520

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187004745A Active KR102690998B1 (ko) 2015-07-22 2016-07-21 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도

Country Status (22)

Country Link
US (2) US11230605B2 (https=)
EP (1) EP3325509B1 (https=)
JP (1) JP6858185B2 (https=)
KR (1) KR102690998B1 (https=)
CN (1) CN107849136B (https=)
AU (1) AU2016296321B2 (https=)
CA (1) CA2992509C (https=)
CY (1) CY1123941T1 (https=)
DK (1) DK3325509T3 (https=)
ES (1) ES2860988T3 (https=)
HR (1) HRP20210393T1 (https=)
HU (1) HUE053296T2 (https=)
IL (1) IL257065B (https=)
LT (1) LT3325509T (https=)
MX (1) MX2018000569A (https=)
PL (1) PL3325509T3 (https=)
PT (1) PT3325509T (https=)
RS (1) RS61586B1 (https=)
RU (1) RU2737637C2 (https=)
SI (1) SI3325509T1 (https=)
SM (1) SMT202100134T1 (https=)
WO (1) WO2017013230A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
FR3062213B1 (fr) 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP4069745A4 (en) * 2019-11-06 2024-05-29 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR 1 TARGETING
CN115427059A (zh) * 2020-01-31 2022-12-02 达因疗法公司 抗转铁蛋白受体（tfr）抗体及其用途
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) * 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023034409A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
US20240376222A1 (en) * 2021-09-13 2024-11-14 The Board Of Regents Of The University Of Texas System Tfr antigen binding proteins and uses thereof
IL316143A (en) * 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
AU2023404617A1 (en) * 2022-12-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-tfr1 antibodies and uses thereof
CN120958020A (zh) 2023-03-24 2025-11-14 戴纳立制药公司 Aβ靶向蛋白和使用方法
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
TW202517685A (zh) * 2023-10-26 2025-05-01 美商百健Ｍａ公司 抗運鐵蛋白受體抗體及其用途
WO2025140522A1 (en) * 2023-12-29 2025-07-03 Nona Biosciences (Suzhou) Co., Ltd. Anti-tfr1 antibodies, preparation methods and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2011073943A1 (fr) 2009-12-16 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
WO2014020140A1 (en) 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
PL209392B1 (pl) * 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2005011082A2 (en) 2003-07-23 2005-02-03 Univeral Infusion Technology Drive motor transmission system
JP4824025B2 (ja) * 2004-06-07 2011-11-24 マクロジェニックス ウエスト，インコーポレイテッド トランスフェリンレセプター抗体
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CA2893794C (en) * 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
EP3552631A1 (en) * 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111082A1 (en) 2004-04-30 2005-11-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-tfr antibody.
WO2011073943A1 (fr) 2009-12-16 2011-06-23 Centre National De La Recherche Scientifique (Cnrs) Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
WO2014020140A1 (en) 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia

Also Published As

Publication number Publication date
EP3325509A1 (en) 2018-05-30
US20220119543A1 (en) 2022-04-21
JP6858185B2 (ja) 2021-04-14
US12037408B2 (en) 2024-07-16
RU2018106364A3 (https=) 2019-08-22
RS61586B1 (sr) 2021-04-29
AU2016296321A1 (en) 2018-01-25
PL3325509T3 (pl) 2021-07-19
AU2016296321B2 (en) 2022-09-08
CY1123941T1 (el) 2022-05-27
RU2018106364A (ru) 2019-08-22
HUE053296T2 (hu) 2021-06-28
LT3325509T (lt) 2021-06-10
HK1256088A1 (en) 2019-09-13
CN107849136B (zh) 2022-04-01
SMT202100134T1 (it) 2021-05-07
KR20180028519A (ko) 2018-03-16
EP3325509B1 (en) 2020-12-16
MX2018000569A (es) 2018-09-27
US20190092870A1 (en) 2019-03-28
WO2017013230A1 (en) 2017-01-26
RU2737637C2 (ru) 2020-12-01
CA2992509C (en) 2025-02-04
JP2018521691A (ja) 2018-08-09
PT3325509T (pt) 2021-03-12
ES2860988T3 (es) 2021-10-05
DK3325509T3 (da) 2021-03-08
CN107849136A (zh) 2018-03-27
HRP20210393T1 (hr) 2021-04-30
CA2992509A1 (en) 2017-01-26
BR112018000650A2 (en) 2018-09-18
IL257065A (en) 2018-03-29
US11230605B2 (en) 2022-01-25
IL257065B (en) 2022-07-01
SI3325509T1 (sl) 2021-07-30

Similar Documents

Publication Publication Date Title
US12037408B2 (en) Method of treating a tumor using anti-TfR antibodies
AU2019204016B2 (en) Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
AU2020286284B2 (en) Novel anti-CD39 antibodies
KR102847971B1 (ko) 항체-약물 컨쥬게이트 및 이의 암 치료 용도
JP7419238B2 (ja) Ｐｄ１結合剤
KR20230170672A (ko) 항-cd122 항체 및 이의 용도
CN114981301B (zh) Pd1和vegfr2双结合剂
CN116133684B (zh) 抗人nr1抗体衍生物
KR20210076918A (ko) 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도
KR20230113752A (ko) Cd39 및 tgf베타를 표적화하는 신규 접합체 분자
WO2024175030A1 (zh) 抗Nectin-4抗体和包含其的多特异性抗体
WO2021258337A1 (en) Human monoclonal antibodies against tigit for immune related diseases
KR102882299B1 (ko) 항체 및 사용 방법
JP2022547135A (ja) 増強されたプロテインｌ捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders
CN117295762A (zh) 抗cd122抗体及其用途
WO2024251154A1 (zh) 抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
CN121270705A (zh) 抗cMET抗体
CN120607616A (zh) 抗IL-1β抗体及其用途
CN121226557A (zh) 抗cMET抗体
CN121226555A (zh) 抗cMET抗体
BR112018000650B1 (pt) Anticorpos anti-trf e sua utilização no tratamento de transtornos proliferativos e inflamatórios

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180219

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210526

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230719

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240626

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240729

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240729

End annual number: 3

Start annual number: 1

PG1601 Publication of registration